Cardiac Mapping Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Cardiac Mapping Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The cardiac mapping market is projected to register a CAGR of 8.5% during the forecast period (2022 - 2027).

The COVID-19 pandemic harmed the cardiac mapping market. Various research studies have been published to provide insight into the impact of the pandemic on the market. For instance, a research study published titled "Cardiac Involvement of COVID-19: A Comprehensive Review" published in January 2021 stated that COVID-19 can significantly affect patients' cardiovascular systems. Mortality from COVID-19 is strongly associated with cardiovascular disease, diabetes, and hypertension. Hence, patients suffering from Cardiovascular diseases must take more precautions against COVID-19, which may require the adoption of cardiac mapping. Similarly, the article titled "Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports" in September 2020 stated there is an increase in morbidity and mortality in patients suffering from both cardiovascular complications and COVID-19. Therefore, more considerable attention is needed to viral infection-related heart damage during treatment. With such studies, the market is likely to increase as it provides the need for cardiac mapping due to the COVID-19 pandemic.

Cardiovascular diseases (CVDs) affect the heart and blood vessels of the body. These diseases affect one or more than one parts of the heart and blood vessels. Patients suffering from CVDs can be symptomatic or asymptomatic. According to the data published by the European Heart network in 2021 reported that in the European Union more than 60 million people live with Cardiovascular disease and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Similarly, According to data from the Longitudinal Ageing Study of India (LASI) released by the Union Ministry of Family and Health Welfare on January 6, 2020, the self-reported prevalence of cardiovascular disease is rising with the age. The same source also reported that the self-reported prevalence of cardiovascular diseases among the adults aged 45-59 is 21.9%, people of age 60-74 is 33.8% and the age more than 75 years is 37.4%.

Factors such as product launches and approvals are key for the growth of the market in the upcoming future. In August 2020, Biosense Webster launched the latest Carto heart mapping system generation. The Carto Prime mapping module adds tools to the Carto 3 platform for further addressing all major complex arrhythmias, with improvements in mapping capabilities that help to reduce ablation times compared to standard mapping algorithms. With such launches, the market is likely to grow in the upcoming future. Product approvals are another factor in the growth of the market. In November 2020, Abbott received CE Mark and approval in Australia for its new EnSite X EP System, launching it throughout Europe and Australia. The EnSite X System is the only system that offers the option to navigate the cardiac anatomy in two different ways on one platform. The EnSite X System has advanced imaging capabilities that create a three-dimensional (3D) model of the patient's cardiac anatomy in real-time, allowing physicians to see areas of the heart that need ablation treatment. With such approvals, the market is likely to grow in the future.

However, the lack of skilled electrophysiologists will likely hinder the market's growth.

Factors such as increasing atrial fibrillation, research studies, and initiatives are expected to drive the growth of the segment in the upcoming future. According to the Centers for Disease Control and Prevention(CDC), in 2020, more than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in United States. It is estimated that 12.1 million people in United States will have atrial fibrillation (AFib) in 2030. Similarly, the article titled ' Epidemiology of Atrial Fibrillation in the 21st Century ' published in June 2020 mentioned that it was estimated that by 2050 Atrial Fibrillation would be diagnosed at least in 72 million individuals in Asia. Such increased incidence of Atrial fibrillation is expected to drive the growth of the studied segment during the forecast period.

Moreover, in June 2021, Cardiac Insights, Inc., a United States-based healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrhythmias, such as atrial fibrillation (Afib) announced launching its Cardea SOLO ECG System at Arab Health 2021, the largest healthcare exhibition in the Middle East. In August 2020, Boston Scientific developed the LUX-Dx implantable cardiac monitoring (ICM) system for the long-term diagnosis of arrhythmias associated with conditions such as atrial fibrillation and syncope. . It received clearance for commercialization in the US under the Class II medical device category in June 2020.

Hence, the abovementioned factors are expected to drive the growth of the studied segment during the forecast period.

The North American region is expected t hold a significant share in the growth of the market during the forecast period.

With the rising focus on patient care and need, supported by the well-developed infrastructure and technologically advanced healthcare system, the increasing burden of cardiac diseases and rising geriatric population is expected to drive the market growth in the region. According to the article titled ' Heart Disease and Stroke' published in February 2022 As cardiac mapping devices are used for properly diagnosing and treating cardiac diseases, the prevalence of cardiac diseases is expected to boost the market's growth.

Also, according to the Centres for Disease Control and Prevention (CDC), in September 2020. Every year, about 805,000 Americans have a heart attack. As the number of deaths due to heart diseases increases, there is a growing demand for the proper detection and diagnosis of cardiac diseases and mapping devices to fulfill the unmet needs. Hence are expected to show growth over the forecast period. According to the article titled ' Heart Disease in Canada' published in July 2022, about 1 in 12 Canadians adults aged 20 and over live with diagnosed heart disease. This increased risk among the Canadian population is driving the market's growth.

Also, the increasing product approvals for the Cardiac mapping in North American region is also expected to drive the growth of the market during the forecast period. For instance, in January 2022 Abbott recived the clearance from the Food and Drug Administrtaion (FDA) for the EnSITE X EP system with EnSite Omnipolar Technology, a cardiac mapping platform in United States.

Hence, the above mentioned factors are expected to drive the growth of the market in the studied region during the forecast period.

The market is partially fragmented and consists of several major players. Biosense Webster, Inc., Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, and Acutus Medical are currently dominating the market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support